Evidence to date: ranibizumab and its potential in the treatment of retinopathy of prematurity

Authors

Samir Patel, Thomas Jefferson UniversityFollow
Michael A. Klufas, Thomas Jefferson University

Document Type

Article

Publication Date

8-23-2019

Comments

This article has been peer reviewed. It is the author’s final published version in Eye and Brain, Volume 11, August 2019, Pages 25-35.

The published version is available at https://doi.org/10.2147/EB.S189684. Copyright © Patel & Klufas

Abstract

Retinopathy of prematurity (ROP) is a leading and preventable cause of childhood blindness worldwide. Although laser photocoagulation remains the gold standard for treatment, the off-label use of anti-vascular endothelial growth factor (anti-VEGF) therapy to treat ROP, particularly posterior zone I disease, is increasing. Although initial studies on anti-VEGF therapy for ROP have focused on bevacizumab, recent studies have proposed that ranibizumab may be a safer and more effective alternative for use in this population. This review updates recent evidence regarding the use of ranibizumab in the management of ROP.

Recommended Citation

Patel, Samir and Klufas, Michael A., "Evidence to date: ranibizumab and its potential in the treatment of retinopathy of prematurity" (2019). Wills Eye Hospital Papers. Paper 99.
https://jdc.jefferson.edu/willsfp/99

Creative Commons License

This work is licensed under a Creative Commons Attribution-Noncommercial 3.0 License

Language

English